You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLosartan
Accession NumberDB00678  (APRD00052)
TypeSmall Molecule
GroupsApproved
DescriptionLosartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. Losartan and its longer acting metabolite, E-3174, lower blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); they compete with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Losartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of systolic dysfunction, myocardial infarction, coronary artery disease, and heart failure.
Structure
Thumb
Synonyms
(2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
2-N-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
DuP 89
Losartan
External Identifiers
  • MK594
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Losartantablet25 mgoralActavis Pharma Company2012-01-25Not applicableCanada
Act Losartantablet50 mgoralActavis Pharma Company2012-01-25Not applicableCanada
Act Losartantablet100 mgoralActavis Pharma Company2012-01-25Not applicableCanada
Ag-losartantablet50 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-losartantablet100 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-losartantablet25 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Auro-losartantablet25.0 mgoralAuro Pharma Inc2013-03-26Not applicableCanada
Auro-losartantablet50.0 mgoralAuro Pharma Inc2013-03-26Not applicableCanada
Auro-losartantablet100.0 mgoralAuro Pharma Inc2013-03-26Not applicableCanada
Bio-losartantablet50 mgoralBiomed Pharma2016-05-09Not applicableCanada
Bio-losartantablet100 mgoralBiomed Pharma2016-06-08Not applicableCanada
Bio-losartantablet25 mgoralBiomed Pharma2016-05-09Not applicableCanada
Cozaartablet, film coated100 mg/1oralREMEDYREPACK INC.2011-04-22Not applicableUs
Cozaartablet, film coated25 mg/1oralMerck Sharp & Dohme Corp.1995-04-14Not applicableUs
Cozaartablet, film coated50 mg/1oralbryant ranch prepack1995-04-14Not applicableUs
Cozaartablet, film coated25 mg/1oralPhysicians Total Care, Inc.2004-06-02Not applicableUs
Cozaartablet100 mgoralMerck Canada Inc1998-01-16Not applicableCanada
Cozaartablet, film coated25 mg/1oralREMEDYREPACK INC.2011-05-19Not applicableUs
Cozaartablet, film coated50 mg/1oralMerck Sharp & Dohme Corp.1995-04-14Not applicableUs
Cozaartablet, film coated100 mg/1oralbryant ranch prepack1995-04-14Not applicableUs
Cozaartablet, film coated25 mg/1oralCardinal Health1995-04-14Not applicableUs
Cozaartablet, film coated100 mg/1oralPhysicians Total Care, Inc.2003-08-06Not applicableUs
Cozaartablet, film coated100 mg/1oralMerck Sharp & Dohme Corp.1995-04-14Not applicableUs
Cozaartablet25 mgoralMerck Canada Inc1995-12-31Not applicableCanada
Cozaartablet, film coated50 mg/1oralCardinal Health1995-04-14Not applicableUs
Cozaartablet25 mg/1oralREMEDYREPACK INC.2011-04-07Not applicableUs
Cozaartablet, film coated50 mg/1oralPhysicians Total Care, Inc.1996-04-01Not applicableUs
Cozaartablet50 mgoralMerck Canada Inc1995-12-31Not applicableCanada
Cozaartablet, film coated100 mg/1oralPd Rx Pharmaceuticals, Inc.1995-04-14Not applicableUs
Ipg-losartantablet50 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-losartantablet25 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-losartantablet100 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-losartantablet25 mgoralJamp Pharma Corporation2013-06-11Not applicableCanada
Jamp-losartantablet50 mgoralJamp Pharma Corporation2013-06-11Not applicableCanada
Jamp-losartantablet100 mgoralJamp Pharma Corporation2013-06-11Not applicableCanada
Losartantablet25 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Losartantablet50 mgoralSivem Pharmaceuticals Ulc2012-07-05Not applicableCanada
Losartantablet25 mgoralFrosst A Division Of Merck Canada IncNot applicableNot applicableCanada
Losartantablet50 mgoralPro Doc Limitee2012-11-22Not applicableCanada
Losartantablet25 mgoralSanis Health Inc2012-07-20Not applicableCanada
Losartantablet50 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Losartantablet100 mgoralSivem Pharmaceuticals Ulc2012-07-05Not applicableCanada
Losartantablet25 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Losartantablet50 mgoralFrosst A Division Of Merck Canada IncNot applicableNot applicableCanada
Losartantablet100 mgoralPro Doc Limitee2012-11-22Not applicableCanada
Losartantablet50 mgoralSanis Health Inc2012-07-20Not applicableCanada
Losartantablet100 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Losartantablet50 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Losartantablet100 mgoralFrosst A Division Of Merck Canada IncNot applicableNot applicableCanada
Losartantablet100 mgoralSanis Health Inc2012-07-20Not applicableCanada
Losartantablet25 mgoralPro Doc Limitee2012-11-22Not applicableCanada
Losartantablet100 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Losartantablet25 mgoralSivem Pharmaceuticals Ulc2012-07-05Not applicableCanada
Losartan Potassiumtablet50 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Losartan Potassiumtablet, film coated50 mg/1oralSandoz Inc.1995-04-14Not applicableUs
Losartan Potassiumtablet50 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Losartan Potassiumtablet25 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Losartan Potassiumtablet, film coated100 mg/1oralSandoz Inc.1995-04-14Not applicableUs
Losartan Potassiumtablet100 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Losartan Potassiumtablet25 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Losartan Potassiumtablet100 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Losartan Potassiumtablet, film coated25 mg/1oralSandoz Inc.1995-04-14Not applicableUs
Mar-losartantablet25 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-losartantablet50 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-losartantablet100 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mint-losartantablet100.0 mgoralMint Pharmaceuticals Inc2014-01-16Not applicableCanada
Mint-losartantablet25.0 mgoralMint Pharmaceuticals Inc2014-01-16Not applicableCanada
Mint-losartantablet50.0 mgoralMint Pharmaceuticals Inc2014-01-16Not applicableCanada
Mylan-losartantablet25 mgoralMylan Pharmaceuticals Ulc2012-01-25Not applicableCanada
Mylan-losartantablet50 mgoralMylan Pharmaceuticals Ulc2012-01-25Not applicableCanada
Mylan-losartantablet100 mgoralMylan Pharmaceuticals Ulc2012-01-25Not applicableCanada
PMS-losartantablet100 mgoralPharmascience Inc2012-01-25Not applicableCanada
PMS-losartantablet25 mgoralPharmascience Inc2012-01-25Not applicableCanada
PMS-losartantablet50 mgoralPharmascience Inc2012-01-25Not applicableCanada
Priva-losartantablet50 mgoralPharmapar Inc2016-05-09Not applicableCanada
Priva-losartantablet100 mgoralPharmapar Inc2016-05-25Not applicableCanada
Priva-losartantablet25 mgoralPharmapar Inc2016-05-25Not applicableCanada
Ran-losartantablet50 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-losartantablet100 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-losartantablet25 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Sandoz Losartantablet25 mgoralSandoz Canada Incorporated2012-01-25Not applicableCanada
Sandoz Losartantablet50 mgoralSandoz Canada Incorporated2012-01-25Not applicableCanada
Sandoz Losartantablet100 mgoralSandoz Canada Incorporated2012-01-25Not applicableCanada
Septa-losartantablet25 mgoralSepta Pharmaceuticals Inc2014-07-03Not applicableCanada
Septa-losartantablet50 mgoralSepta Pharmaceuticals Inc2014-07-03Not applicableCanada
Septa-losartantablet100 mgoralSepta Pharmaceuticals Inc2014-07-03Not applicableCanada
Teva-losartantablet50 mgoralTeva Canada Limited2012-01-25Not applicableCanada
Teva-losartantablet25 mgoralTeva Canada Limited2012-02-28Not applicableCanada
Teva-losartantablet100 mgoralTeva Canada Limited2012-01-25Not applicableCanada
Van-losartantablet100 mgoralVanc Pharmaceuticals Inc2015-06-08Not applicableCanada
Van-losartantablet25 mgoralVanc Pharmaceuticals Inc2015-06-08Not applicableCanada
Van-losartantablet50 mgoralVanc Pharmaceuticals Inc2015-06-08Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-losartantablet100 mgoralApotex Inc2012-01-25Not applicableCanada
Apo-losartantablet25 mgoralApotex Inc2012-04-13Not applicableCanada
Apo-losartantablet50 mgoralApotex Inc2012-01-25Not applicableCanada
Losartantablet, film coated100 mg/1oralVirtus Pharmaceuticals2015-07-14Not applicableUs
Losartantablet, film coated25 mg/1oralVirtus Pharmaceuticals2015-07-14Not applicableUs
Losartantablet, film coated50 mg/1oralVirtus Pharmaceuticals2015-07-14Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralMylan Pharmaceuticals Inc.2012-12-06Not applicableUs
Losartan Potassiumtablet25 mg/1oralTorrent Pharmaceuticals Limited2010-10-06Not applicableUs
Losartan Potassiumtablet100 mg/1oralPreferred Pharmaceuticals, Inc.2015-05-07Not applicableUs
Losartan Potassiumtablet100 mg/1oralUnit Dose Services2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralSandoz Inc2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralMed Vantx, Inc.2010-10-03Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralApotex Corp2010-10-03Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralPhysicians Total Care, Inc.2010-04-27Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralCamber Pharmaceuticals, Inc.2015-08-19Not applicableUs
Losartan Potassiumtablet25 mg/1oralRoxane Laboratories, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralCarilion Materials Management2010-04-06Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralQualitest Pharmaceuticals2012-01-04Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralLegacy Pharmaceutical Packaging, Llc2010-04-06Not applicableUs
Losartan Potassiumtablet25 mg/1oralREMEDYREPACK INC.2011-12-07Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralVirtus Pharmaceuticals LLC2014-03-25Not applicableUs
Losartan Potassiumtablet50 mg/1oralDIRECT RX2015-01-01Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralReady Meds2012-01-04Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralClinical Solutions Wholesale2010-04-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2010-10-03Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-11-12Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralMacleods Pharmaceuticals Limited2012-05-10Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralWatson Laboratories, Inc.2011-02-22Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralLegacy Pharmaceutical Packaging, Llc2010-04-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralRising Pharmaceuticals, Inc2014-07-30Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralSolco Healthcare US, LLC2014-07-30Not applicableUs
Losartan Potassiumtablet100 mg/1oralREMEDYREPACK INC.2013-05-14Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralAvera Mc Kennan Hospital2015-03-09Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralAurobindo Pharma Limited2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralGolden State Medical Supply, Inc.2011-02-22Not applicableUs
Losartan Potassiumtablet100 mg/1oralUnichem Pharmaceuticals (USA), Inc.2016-01-01Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralTeva Pharmaceuticals USA Inc2010-04-06Not applicableUs
Losartan Potassiumtablet25 mg/1oralLupin Pharmaceuticals, Inc.2015-12-02Not applicableUs
Losartan Potassiumtablet100 mg/1oralMajor Pharmaceuticals2014-06-09Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralPreferred Pharmaceuticals, Inc.2011-03-21Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralMicro Labs Limited2012-12-06Not applicableUs
Losartan Potassiumtablet100 mg/1oralAv Pak2014-03-27Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralMylan Pharmaceuticals Inc.2012-12-06Not applicableUs
Losartan Potassiumtablet100 mg/1oralTorrent Pharmaceuticals Limited2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralPd Rx Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralREMEDYREPACK INC.2013-02-26Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralSandoz Inc2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralMed Vantx, Inc.2010-12-28Not applicableUs
Losartan Potassiumtablet50 mg/1oralSt Marys Medical Park Pharmacy2013-07-11Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Losartan Potassiumtablet50 mg/1oralRoxane Laboratories, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet25 mg/1oralLupin Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralLegacy Pharmaceutical Packaging2010-10-03Not applicableUs
Losartan Potassiumtablet100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralREMEDYREPACK INC.2013-03-08Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralVirtus Pharmaceuticals LLC2014-03-25Not applicableUs
Losartan Potassiumtablet25 mg/1oralDIRECT RX2015-12-03Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralCadila Healthcare Limited2010-10-04Not applicableUs
Losartan Potassiumtablet50 mg/1oralLife Line Home Care Services, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralREMEDYREPACK INC.2013-05-15Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralKAISER FOUNDATION HOSPITALS2016-03-16Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2010-10-03Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-11-12Not applicableUs
Losartan Potassiumtablet100 mg/1oralClinical Solutions Wholesale2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralMacleods Pharmaceuticals Limited2012-06-01Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralWatson Laboratories, Inc.2011-02-22Not applicableUs
Losartan Potassiumtablet50 mg/1oralLegacy Pharmaceutical Packaging2011-02-21Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralRising Pharmaceuticals, Inc2014-07-30Not applicableUs
Losartan Potassiumtablet50 mg/1oralLupin Pharmaceuticals, Inc.2015-12-02Not applicableUs
Losartan Potassiumtablet50 mg/1oralMajor Pharmaceuticals2014-06-09Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralPreferred Pharmaceuticals, Inc.2013-01-25Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralMicro Labs Limited2012-12-06Not applicableUs
Losartan Potassiumtablet25 mg/1oralUnit Dose Services2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralProficient Rx LP2012-01-04Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralAurobindo Pharma Limited2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralApotex Corp2010-10-03Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralPhysicians Total Care, Inc.2010-04-13Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralCamber Pharmaceuticals, Inc.2015-08-19Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralTeva Pharmaceuticals USA Inc2010-04-06Not applicableUs
Losartan Potassiumtablet100 mg/1oralSt Marys Medical Park Pharmacy2013-07-11Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralMylan Pharmaceuticals Inc.2012-12-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralTorrent Pharmaceuticals Limited2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralSolco Healthcare US, LLC2011-06-01Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralREMEDYREPACK INC.2012-12-27Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralREMEDYREPACK INC.2015-09-17Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralbryant ranch prepack2010-10-03Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralDispensing Solutions, Inc.2010-12-28Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralCadila Healthcare Limited2010-10-04Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralGolden State Medical Supply, Inc.2011-02-22Not applicableUs
Losartan Potassiumtablet100 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Losartan Potassiumtablet25 mg/1oralUnichem Pharmaceuticals (USA), Inc.2016-01-01Not applicableUs
Losartan Potassiumtablet100 mg/1oralRoxane Laboratories, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralLupin Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralLegacy Pharmaceutical Packaging, Llc2010-10-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-06Not applicableUs
Losartan Potassiumtablet25 mg/1oralAv Pak2014-03-27Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralAvera Mc Kennan Hospital2015-03-11Not applicableUs
Losartan Potassiumtablet100 mg/1oralDIRECT RX2014-01-01Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralLegacy Pharmaceutical Packaging, Llc2010-04-06Not applicableUs
Losartan Potassiumtablet100 mg/1oralSTAT Rx USA LLC2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralMc Kesson Contract Packaging2013-04-10Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralMedsource Pharmaceuticals2010-04-06Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralKAISER FOUNDATION HOSPITALS2016-03-16Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralMc Kesson Packaging Services2010-10-04Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-11-12Not applicableUs
Losartan Potassiumtablet50 mg/1oralClinical Solutions Wholesale2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralMacleods Pharmaceuticals Limited2012-06-01Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralQualitest Pharmaceuticals2012-01-04Not applicableUs
Losartan Potassiumtablet100 mg/1oralLupin Pharmaceuticals, Inc.2015-12-02Not applicableUs
Losartan Potassiumtablet25 mg/1oralMajor Pharmaceuticals2014-06-09Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralPreferred Pharmaceuticals, Inc.2013-01-25Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralMicro Labs Limited2012-12-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralUnit Dose Services2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralSandoz Inc2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralProficient Rx LP2010-04-06Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralAurobindo Pharma Limited2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralApotex Corp2010-10-03Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralPhysicians Total Care, Inc.2010-04-13Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralCamber Pharmaceuticals, Inc.2015-08-19Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralKAISER FOUNDATION HOSPITALS2015-12-01Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2010-10-03Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralDispensing Solutions, Inc.2010-12-28Not applicableUs
Losartan Potassiumtablet25 mg/1oralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralCardinal Health2011-08-12Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralWatson Laboratories, Inc.2011-02-22Not applicableUs
Losartan Potassiumtablet25 mg/1oralLegacy Pharmaceutical Packaging2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralRising Pharmaceuticals, Inc2011-06-01Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralSolco Healthcare US, LLC2014-07-30Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralPd Rx Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralCadila Healthcare Limited2010-10-04Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralGolden State Medical Supply, Inc.2011-02-22Not applicableUs
Losartan Potassiumtablet50 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Losartan Potassiumtablet50 mg/1oralUnichem Pharmaceuticals (USA), Inc.2016-01-01Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralTeva Pharmaceuticals USA Inc2010-04-06Not applicableUs
Losartan Potassiumtablet100 mg/1oralLupin Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralPreferred Pharmaceuticals, Inc.2013-06-06Not applicableUs
Losartan Potassiumtablet25 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralAv Pak2014-03-27Not applicableUs
Losartan Potassiumtablet100 mg/1oralLegacy Pharmaceutical Packaging2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralVirtus Pharmaceuticals LLC2014-03-25Not applicableUs
Losartan Potassiumtablet25 mg/1oralREMEDYREPACK INC.2011-07-15Not applicableUs
Losartan Potassiumtablet25 mg/1oralREMEDYREPACK INC.2014-04-09Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralPd Rx Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralReady Meds2012-01-04Not applicableUs
Losartan Potassiumtablet25 mg/1oralCarilion Materials Management2010-10-06Not applicableUs
Losartan Potassiumtablet100 mg/1oralREMEDYREPACK INC.2015-03-07Not applicableUs
Losartan Potassiumtablet25 mg/1oralClinical Solutions Wholesale2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralQualitest Pharmaceuticals2012-01-04Not applicableUs
Losartan Potassium Tablets, 100 mgtablet100 mg/1oralJubilant Cadista Pharmaceuticals Inc.2012-09-18Not applicableUs
Losartan Potassium Tablets, 25 mgtablet25 mg/1oralJubilant Cadista Pharmaceuticals Inc.2012-09-18Not applicableUs
Losartan Potassium Tablets, 50 mgtablet50 mg/1oralJubilant Cadista Pharmaceuticals Inc.2012-09-18Not applicableUs
Losartan Potatssiumtablet50 mg/1oralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Losortan Potassiumtablet, film coated25 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralPd Rx Pharmaceuticals, Inc.2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralbryant ranch prepack2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralRebel Distributors Corp2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-14Not applicableUs
Losortan Potassiumtablet, film coated25 mg/1oralAmerican Health Packaging2013-06-13Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralCardinal Health2013-06-13Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralProficient Rx LP2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralCardinal Health2010-10-14Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralAidarex Pharmaceuticals LLC2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralbryant ranch prepack2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated25 mg/1oralRebel Distributors Corp2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralMedsource Pharmaceuticals2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralAmerican Health Packaging2013-06-13Not applicableUs
Losortan Potassiumtablet, film coated25 mg/1oralCardinal Health2010-10-14Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralAidarex Pharmaceuticals LLC2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated25 mg/1oralREMEDYREPACK INC.2014-04-01Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralAmerican Health Packaging2013-06-13Not applicableUs
Losortan Potassiumtablet, film coated25 mg/1oralAidarex Pharmaceuticals LLC2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralREMEDYREPACK INC.2013-06-03Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralProficient Rx LP2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralRebel Distributors Corp2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-14Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LortaanNot Available
Brand mixtures
NameLabellerIngredients
Act Losartan/hctActavis Pharma Company
Apo-losartan/hctzApotex Inc
Auro-losartan HctAuro Pharma Inc
HyzaarMerck Sharp & Dohme Corp.
Hyzaar 50/12.5mgMerck Canada Inc
Hyzaar DS 100/25 mgMerck Canada Inc
Jamp-losartan HctzJamp Pharma Corporation
Losartan Potassium and HydrochlorothiazideRoxane Laboratories, Inc.
Losartan-hctzPro Doc Limitee
Losartan/hctSivem Pharmaceuticals Ulc
Losartan/hctzSanis Health Inc
Mint-losartan/hctzMint Pharmaceuticals Inc
Mint-losartan/hctz DSMint Pharmaceuticals Inc
Mylan-losartan HctzMylan Pharmaceuticals Ulc
PMS-losartan-hctzPharmascience Inc
Ratio-losartan HctzTeva Canada Limited
Sandoz Losartan HctSandoz Canada Incorporated
Sandoz Losartan Hct DSSandoz Canada Incorporated
Septa-losartan HctzSepta Pharmaceuticals Inc
Teva-losartan/hctzTeva Canada Limited
Van-losartan-hctzVanc Pharmaceuticals Inc
Salts
Name/CASStructureProperties
Losartan Potassium
Thumb
  • InChI Key: OXCMYAYHXIHQOA-UHFFFAOYSA-N
  • Monoisotopic Mass: 460.118068924
  • Average Mass: 461.001
DBSALT000112
Categories
UNIIJMS50MPO89
CAS number114798-26-4
WeightAverage: 422.911
Monoisotopic: 422.162187095
Chemical FormulaC22H23ClN6O
InChI KeyInChIKey=PSIFNNKUMBGKDQ-UHFFFAOYSA-N
InChI
InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
IUPAC Name
[2-butyl-4-chloro-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazol-5-yl]methanol
SMILES
CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as biphenyltetrazoles and derivatives. These are organic compounds containing a biphenyl attached to a tetrazole. A carbon atom of the biphenyl moiety is boned to a carbon or the nitrogen atom of the tetrazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassTetrazoles
Direct ParentBiphenyltetrazoles and derivatives
Alternative Parents
Substituents
  • Biphenyltetrazole
  • Biphenyl
  • 1,2,4,5-tetrasubstituted imidazole
  • Phenylmethylamine
  • Benzenoid
  • N-substituted imidazole
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Imidazole
  • Azacycle
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationMay be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
PharmacodynamicsLosartan is the first of a class of antihypertensive agents called angiotensin II receptor blockers (ARBs). Losartan and its longer acting active metabolite, E-3174, are specific and selective type-1 angiotensin II receptor (AT1) antagonists which block the blood pressure increasing effects angiotensin II via the renin-angiotensin-aldosterone system (RAAS). RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: AT1 and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.
Mechanism of actionLosartan competitively inhibits the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. Losartan is metabolized to its active metabolite, E-3174, which is 10 to 40 times more potent than losartan and acts as a non-competitive AT1 antagonist. Inhibition of angiotensin II binding to AT1 inhibits its AT1-mediated vasoconstrictive and aldosterone-secreting effects and results in decreased vascular resistance and blood pressure. Losartan is 1,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion. Losartan is effective for reducing blood pressure and may be used to treat essential hypertension, left ventricular hypertrophy and diabetic nephropathy.
Related Articles
AbsorptionLosartan is well absorbed and undergoes substantial first-pass metabolism; the systemic bioavailability of losartan is approximately 33%. Mean peak concentrations of losartan and its active metabolite are reached in 1 hour and in 3-4 hours, respectively. While maximum plasma concentrations of losartan and its active metabolite are approximately equal, the AUC of the metabolite is about 4 times as great as that of losartan. When given with a meal, absorption is slows down and Cmax decreases.
Volume of distribution
  • 34 L [losartan, healthy subjects]
  • 12 L [active metabolite, healthy subjects]
Protein binding99.7% protein bound, primarily to albumin
Metabolism

Hepatic. Losartan is metabolized to a 5-carboxylic acid derivative (E-3174) via an aldehyde intermediate (E-3179) primarily by cytochrome P450 (CYP) 2C9 and CYP3A4. E-3174 is an active metabolite with 10- to 40-fold higher potency than its parent compound, losartan. Approxiamtely 14% of losartan is converted to E-3174; however, the AUC of E-3174 was found to be 4- to 8-fold higher than losartan and E-3174 is considered the main contributor to the pharmacologic effects of this medication.

SubstrateEnzymesProduct
Losartan
E-3179Details
Losartan
Losartan N2-glucuronideDetails
E-3179
E-3174Details
Route of eliminationFollowing oral administration of losartan, 35% of the dose is recovered in the urine and about 60% in the feces. Following an intravenous dose, 45% is recovered in the urine and 50% in the feces.
Half lifeThe terminal t1/2 of losartan is 2 hours. The active metabolite has a half-life of 6-9 hours.
Clearance
  • Total plasma clearance = 600 mL/min [losartan]
  • Total plasma clearance = 50 mL/min [active metabolite]
  • Renal clearance = 75 mL/min [losartan]
  • Renal clearance = 25 mL/min [active metabolite]
ToxicityHypotension and tachycardia; Bradycardia could occur from parasympathetic (vagal) stimulation, LD50= 1000 mg/kg (orally in rat)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Losartan Action PathwayDrug actionSMP00162
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier-0.7812
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.6993
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IIInhibitor0.5309
Renal organic cation transporterNon-inhibitor0.5689
CYP450 2C9 substrateNon-substrate0.6839
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.6226
CYP450 1A2 substrateInhibitor0.5514
CYP450 2C9 inhibitorNon-inhibitor0.5423
CYP450 2D6 inhibitorNon-inhibitor0.8102
CYP450 2C19 inhibitorInhibitor0.6288
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7049
Ames testNon AMES toxic0.5382
CarcinogenicityNon-carcinogens0.6595
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6055 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5781
hERG inhibition (predictor II)Inhibitor0.8084
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Merck research laboratories div merck co inc
  • Teva pharmaceuticals usa inc
  • Merck & Co., Inc.
Packagers
Dosage forms
FormRouteStrength
Tabletoral100.0 mg
Tabletoral25.0 mg
Tabletoral50.0 mg
Tabletoral100 mg
Tabletoral25 mg
Tabletoral50 mg
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Tablet, film coatedoral
Tabletoral100 mg/1
Tabletoral25 mg/1
Tabletoral50 mg/1
Tabletoral
Prices
Unit descriptionCostUnit
Losartan Potassium 90 50 mg tablet Bottle211.78USD bottle
Losartan Potassium-HCTZ 30 50-12.5 mg tablet Bottle78.05USD bottle
Hyzaar 100-25 mg tablet3.91USD tablet
Hyzaar 100-12.5 mg tablet3.87USD tablet
Hyzaar 100-12.5 tablet3.61USD tablet
Hyzaar 100-25 tablet3.61USD tablet
Losartan Potassium-HCTZ 100-12.5 mg tablet3.54USD tablet
Losartan Potassium-HCTZ 100-25 mg tablet3.54USD tablet
Cozaar 100 mg tablet3.41USD tablet
Losartan potassium 100 mg tablet3.14USD tablet
Hyzaar 50-12.5 mg tablet2.97USD tablet
Hyzaar 50-12.5 tablet2.65USD tablet
Cozaar 50 mg tablet2.5USD tablet
Losartan potassium 50 mg tablet2.26USD tablet
Cozaar 25 mg tablet1.92USD tablet
Losartan potassium 25 mg tablet1.72USD tablet
Cozaar 100 mg Tablet1.31USD tablet
Cozaar 25 mg Tablet1.31USD tablet
Cozaar 50 mg Tablet1.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1334092 No1995-01-242012-01-24Canada
CA2085584 No2003-02-112011-06-07Canada
US5210079 No1993-11-112010-11-11Us
US5608075 No1992-03-042009-03-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point184 °CPhysProp
water solubility0.82 mg/LNot Available
logP6.1Not Available
pKa5.5MERCK INDEX (1996); approx.
Predicted Properties
PropertyValueSource
Water Solubility0.0047 mg/mLALOGPS
logP4.5ALOGPS
logP5.08ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)7.4ChemAxon
pKa (Strongest Basic)4.12ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.51 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity131.85 m3·mol-1ChemAxon
Polarizability44.86 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Gordon C. Campbell, Jr., Anil M. Dwivedi, Dorothy A. Levorse, James A. McCauley, Krishnaswamy S. Raghavan, “Polymorphs of losartan and the process for the preparation of form II of losartan.” U.S. Patent US5608075, issued May, 1994.

US5608075
General References
  1. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995-1003. [PubMed:11937178 ]
  2. Guo ZX, Qiu MC: [Losartan downregulates the expression of transforming growth factor beta type I and type II receptors in kidney of diabetic rat]. Zhonghua Nei Ke Za Zhi. 2003 Jun;42(6):403-8. [PubMed:12895325 ]
  3. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC: Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006 Apr 7;312(5770):117-21. [PubMed:16601194 ]
  4. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066 ]
  5. Stanfield, Cindy L.;Germann, William J. (2009). Principles of Human Physiology (3rd ed.). Benjamin-Cummings Publishing Company. [ISBN:978-0321556660 ]
  6. Bader, M. (2004). Renin-angiotensin-aldosterone system. In Encyclopedic reference of molecular pharmacology (pp. 810-814). Berlin: Springer. [ISBN:9783540298328 ]
External Links
ATC CodesC09CA01C09DB06C09DA01
AHFS Codes
  • 24:32.08
PDB EntriesNot Available
FDA labelDownload (212 KB)
MSDSDownload (19 KB)
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Losartan can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.
2-mercaptobenzothiazoleThe metabolism of Losartan can be decreased when combined with 2-mercaptobenzothiazole.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Losartan.
AbirateroneThe serum concentration of Losartan can be increased when it is combined with Abiraterone.
AcebutololLosartan may increase the hypotensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Losartan is combined with Aceclofenac.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Losartan.
AcetaminophenThe serum concentration of Losartan can be increased when it is combined with Acetaminophen.
AcetazolamideThe risk or severity of adverse effects can be increased when Losartan is combined with Acetazolamide.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Losartan is combined with Adapalene.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Losartan.
AlbendazoleThe serum concentration of Losartan can be increased when it is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Losartan.
AldosteroneThe serum concentration of Losartan can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Losartan.
AlectinibThe serum concentration of Losartan can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Losartan can be increased when it is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the hypotensive activities of Losartan.
AliskirenLosartan may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Losartan.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Losartan.
AlosetronThe metabolism of Alosetron can be decreased when combined with Losartan.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Losartan.
AlprenololLosartan may increase the hypotensive activities of Alprenolol.
AmantadineThe serum concentration of Losartan can be increased when it is combined with Amantadine.
AmbrisentanLosartan may increase the hypotensive activities of Ambrisentan.
AmifostineLosartan may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Losartan.
Aminohippuric acidThe serum concentration of Losartan can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Losartan.
AmiodaroneThe serum concentration of Losartan can be decreased when it is combined with Amiodarone.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Losartan.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Losartan.
AmlodipineAmlodipine may increase the hypotensive activities of Losartan.
AmobarbitalAmobarbital may increase the hypotensive activities of Losartan.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Losartan.
AmorolfineThe metabolism of Losartan can be decreased when combined with Amorolfine.
Amphotericin BThe metabolism of Losartan can be decreased when combined with Amphotericin B.
AmprenavirThe serum concentration of Losartan can be decreased when it is combined with Amprenavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Losartan.
AmsacrineThe serum concentration of Losartan can be increased when it is combined with Amsacrine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Losartan is combined with Amyl Nitrite.
AN2690The metabolism of Losartan can be decreased when combined with AN2690.
AnidulafunginThe metabolism of Losartan can be decreased when combined with Anidulafungin.
AntipyrineThe risk or severity of adverse effects can be increased when Losartan is combined with Antipyrine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Losartan.
ApraclonidineThe risk or severity of adverse effects can be increased when Losartan is combined with Apraclonidine.
ApremilastThe risk or severity of adverse effects can be increased when Losartan is combined with Apremilast.
AprepitantThe serum concentration of Losartan can be increased when it is combined with Aprepitant.
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Losartan.
ArdeparinArdeparin may increase the hyperkalemic activities of Losartan.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Losartan.
AripiprazoleAripiprazole may increase the hypotensive activities of Losartan.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Losartan.
ArtemetherThe metabolism of Losartan can be decreased when combined with Artemether.
AstemizoleThe serum concentration of Losartan can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Losartan.
AtenololAtenolol may increase the hypotensive activities of Losartan.
AtomoxetineThe metabolism of Losartan can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Losartan can be increased when it is combined with Atorvastatin.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Losartan.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Losartan.
AzapropazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Losartan is combined with Azelastine.
AzelastineThe serum concentration of Losartan can be increased when it is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Losartan is combined with Azilsartan medoxomil.
AzithromycinThe serum concentration of Losartan can be increased when it is combined with Azithromycin.
Bafilomycin A1The metabolism of Losartan can be decreased when combined with Bafilomycin A1.
BalsalazideThe risk or severity of adverse effects can be increased when Losartan is combined with Balsalazide.
BarbitalBarbital may increase the hypotensive activities of Losartan.
BemiparinBemiparin may increase the hyperkalemic activities of Losartan.
BenazeprilBenazepril may increase the hypotensive activities of Losartan.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Losartan.
BenmoxinBenmoxin may increase the hypotensive activities of Losartan.
BenoxaprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Benoxaprofen.
BenzocaineThe serum concentration of Losartan can be increased when it is combined with Benzocaine.
Benzoic AcidThe metabolism of Losartan can be decreased when combined with Benzoic Acid.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Losartan.
BepridilLosartan may increase the hypotensive activities of Bepridil.
BeraprostThe metabolism of Beraprost can be decreased when combined with Losartan.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Losartan.
BetaxololBetaxolol may increase the hypotensive activities of Losartan.
BethanidineBethanidine may increase the hypotensive activities of Losartan.
BexaroteneThe serum concentration of Losartan can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Losartan.
BifonazoleThe metabolism of Losartan can be decreased when combined with Bifonazole.
BimatoprostLosartan may increase the hypotensive activities of Bimatoprost.
BiperidenThe serum concentration of Losartan can be increased when it is combined with Biperiden.
BisoprololBisoprolol may increase the hypotensive activities of Losartan.
BoceprevirThe metabolism of Losartan can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Losartan.
BortezomibThe metabolism of Losartan can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Losartan can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Losartan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Losartan.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Losartan.
BretyliumLosartan may increase the hypotensive activities of Bretylium.
BrimonidineLosartan may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Losartan.
BromfenacThe risk or severity of adverse effects can be increased when Losartan is combined with Bromfenac.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Losartan.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Losartan.
BumetanideThe risk or severity of adverse effects can be increased when Losartan is combined with Bumetanide.
BupranololLosartan may increase the hypotensive activities of Bupranolol.
BuprenorphineThe serum concentration of Losartan can be increased when it is combined with Buprenorphine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Losartan.
BupropionThe metabolism of Bupropion can be decreased when combined with Losartan.
BuspironeThe serum concentration of Losartan can be increased when it is combined with Buspirone.
ButenafineThe metabolism of Losartan can be decreased when combined with Butenafine.
ButoconazoleThe metabolism of Losartan can be decreased when combined with Butoconazole.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Losartan.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Losartan.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Losartan.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Losartan.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Losartan.
CanagliflozinThe risk or severity of adverse effects can be increased when Losartan is combined with Canagliflozin.
CandesartanLosartan may increase the hypotensive activities of Candesartan.
CandicidinThe metabolism of Losartan can be decreased when combined with Candicidin.
CandoxatrilCandoxatril may increase the hypotensive activities of Losartan.
CapecitabineThe metabolism of Losartan can be decreased when combined with Capecitabine.
CaptoprilLosartan may increase the hypotensive activities of Captopril.
CarbamazepineThe serum concentration of Losartan can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Losartan.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Losartan.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Losartan.
CaroxazoneCaroxazone may increase the hypotensive activities of Losartan.
CarprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Losartan.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Losartan.
CarvedilolCarvedilol may increase the hypotensive activities of Losartan.
CaspofunginThe metabolism of Losartan can be decreased when combined with Caspofungin.
CastanospermineThe risk or severity of adverse effects can be increased when Losartan is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Losartan is combined with Celecoxib.
CelecoxibThe metabolism of Losartan can be decreased when combined with Celecoxib.
CeliprololLosartan may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Losartan can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Losartan.
CertoparinCertoparin may increase the hyperkalemic activities of Losartan.
CeruleninThe metabolism of Losartan can be decreased when combined with Cerulenin.
ChloroquineThe risk or severity of adverse effects can be increased when Losartan is combined with Chloroquine.
ChloroquineThe serum concentration of Losartan can be increased when it is combined with Chloroquine.
ChlorothiazideLosartan may increase the hypotensive activities of Chlorothiazide.
ChloroxineThe metabolism of Losartan can be decreased when combined with Chloroxine.
ChlorpromazineThe serum concentration of Losartan can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Losartan can be increased when it is combined with Chlorpropamide.
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Losartan.
ChlorprothixeneThe serum concentration of Losartan can be increased when it is combined with Chlorprothixene.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Losartan.
CholecalciferolThe metabolism of Losartan can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Losartan can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Losartan can be decreased when it is combined with Cholic Acid.
CiclopiroxThe metabolism of Losartan can be decreased when combined with Ciclopirox.
CilazaprilLosartan may increase the hypotensive activities of Cilazapril.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Losartan.
CimetidineThe serum concentration of Losartan can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Losartan.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Losartan.
CiprofloxacinLosartan may increase the arrhythmogenic activities of Ciprofloxacin.
CiprofloxacinThe serum concentration of Losartan can be increased when it is combined with Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be decreased when combined with Losartan.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Losartan.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Losartan.
ClarithromycinThe serum concentration of Losartan can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Losartan can be decreased when combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Losartan is combined with Clevidipine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Losartan.
ClofazimineThe serum concentration of Losartan can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Losartan.
ClomipramineThe serum concentration of Losartan can be increased when it is combined with Clomipramine.
ClonidineClonidine may increase the hypotensive activities of Losartan.
ClonixinThe risk or severity of adverse effects can be increased when Losartan is combined with Clonixin.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Losartan.
ClopidogrelThe metabolism of Losartan can be decreased when combined with Clopidogrel.
ClotrimazoleThe metabolism of Losartan can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Losartan.
CobicistatThe serum concentration of Losartan can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Losartan.
ColchicineThe serum concentration of Losartan can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Losartan can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Losartan can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Losartan.
CrizotinibThe metabolism of Losartan can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Losartan.
CryptenamineLosartan may increase the hypotensive activities of Cryptenamine.
CyclophosphamideThe serum concentration of Losartan can be increased when it is combined with Cyclophosphamide.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Losartan.
CyclosporineThe metabolism of Losartan can be decreased when combined with Cyclosporine.
CyclosporineLosartan may increase the hyperkalemic activities of Cyclosporine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Losartan.
D-LimoneneThe risk or severity of adverse effects can be increased when Losartan is combined with D-Limonene.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Losartan.
DabrafenibThe serum concentration of Losartan can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Losartan.
DaclatasvirThe serum concentration of Losartan can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Losartan can be increased when it is combined with Dactinomycin.
DalteparinDalteparin may increase the hyperkalemic activities of Losartan.
DapagliflozinThe risk or severity of adverse effects can be increased when Losartan is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Losartan.
DapsoneThe metabolism of Dapsone can be decreased when combined with Losartan.
DarunavirThe metabolism of Losartan can be decreased when combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Losartan.
DasatinibThe serum concentration of Losartan can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Losartan can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Losartan.
DebrisoquinLosartan may increase the hypotensive activities of Debrisoquin.
Decanoic AcidThe metabolism of Losartan can be decreased when combined with Decanoic Acid.
DeferasiroxThe serum concentration of Losartan can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Losartan can be decreased when combined with Delavirdine.
DeserpidineLosartan may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Losartan can be increased when it is combined with Desipramine.
DesloratadineThe serum concentration of Losartan can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Losartan can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Losartan.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Losartan.
DextromethorphanThe serum concentration of Losartan can be increased when it is combined with Dextromethorphan.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Losartan.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Losartan.
DiazoxideDiazoxide may increase the hypotensive activities of Losartan.
DiclofenacThe risk or severity of adverse effects can be increased when Losartan is combined with Diclofenac.
DiclofenacThe serum concentration of Losartan can be increased when it is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Losartan is combined with Diclofenamide.
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Losartan.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Losartan.
DiflunisalThe risk or severity of adverse effects can be increased when Losartan is combined with Diflunisal.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Losartan.
DigoxinThe serum concentration of Losartan can be decreased when it is combined with Digoxin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Losartan.
DihydroergotamineThe metabolism of Losartan can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Losartan.
DiltiazemDiltiazem may increase the hypotensive activities of Losartan.
DinutuximabThe risk or severity of adverse effects can be increased when Losartan is combined with Dinutuximab.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Losartan.
DipyridamoleThe risk or severity of adverse effects can be increased when Losartan is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Losartan.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Losartan.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Losartan.
DonepezilThe metabolism of Donepezil can be decreased when combined with Losartan.
DopamineThe metabolism of Dopamine can be decreased when combined with Losartan.
DorzolamideLosartan may increase the hypotensive activities of Dorzolamide.
DoxazosinDoxazosin may increase the hypotensive activities of Losartan.
DoxepinThe serum concentration of Losartan can be increased when it is combined with Doxepin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Losartan.
DoxorubicinThe serum concentration of Losartan can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Losartan.
DoxycyclineThe metabolism of Losartan can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Losartan.
DronedaroneThe metabolism of Losartan can be decreased when combined with Dronedarone.
DrospirenoneLosartan may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Losartan is combined with Droxicam.
DuloxetineLosartan may increase the orthostatic hypotensive activities of Duloxetine.
EconazoleThe metabolism of Losartan can be decreased when combined with Econazole.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Losartan.
EfavirenzThe serum concentration of Losartan can be decreased when it is combined with Efavirenz.
EfinaconazoleThe metabolism of Losartan can be decreased when combined with Efinaconazole.
EfonidipineLosartan may increase the hypotensive activities of Efonidipine.
ElbasvirThe serum concentration of Losartan can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Losartan.
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Losartan.
EmpagliflozinThe risk or severity of adverse effects can be increased when Losartan is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Losartan.
EnalaprilatLosartan may increase the hypotensive activities of Enalaprilat.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Losartan.
EnzalutamideThe serum concentration of Losartan can be increased when it is combined with Enzalutamide.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Losartan.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Losartan.
EpirizoleThe risk or severity of adverse effects can be increased when Losartan is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Losartan.
EplerenoneThe risk or severity of adverse effects can be increased when Losartan is combined with Eplerenone.
EpoprostenolLosartan may increase the hypotensive activities of Epoprostenol.
EprosartanLosartan may increase the hypotensive activities of Eprosartan.
ErgonovineThe serum concentration of Losartan can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Losartan can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Losartan.
ErythromycinThe metabolism of Losartan can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Losartan.
Eslicarbazepine acetateThe serum concentration of Losartan can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Losartan.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Losartan.
EstramustineThe serum concentration of Losartan can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Losartan can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Losartan.
EstroneThe serum concentration of Losartan can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Losartan.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Losartan.
Etacrynic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Losartan is combined with Etanercept.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Losartan.
EtodolacThe risk or severity of adverse effects can be increased when Losartan is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Losartan is combined with Etofenamate.
EtoposideThe serum concentration of Losartan can be increased when it is combined with Etoposide.
EtoricoxibThe risk or severity of adverse effects can be increased when Losartan is combined with Etoricoxib.
EtravirineThe serum concentration of Losartan can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Losartan.
Evening primrose oilThe risk or severity of adverse effects can be increased when Losartan is combined with Evening primrose oil.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Losartan.
exisulindThe risk or severity of adverse effects can be increased when Losartan is combined with exisulind.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Losartan.
FelodipineLosartan may increase the hypotensive activities of Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Losartan is combined with Fenbufen.
FenoldopamLosartan may increase the hypotensive activities of Fenoldopam.
FenoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Fenoprofen.
FentanylThe serum concentration of Losartan can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Losartan.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Losartan.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Losartan.
FloctafenineThe risk or severity of adverse effects can be increased when Losartan is combined with Floctafenine.
FloxuridineThe metabolism of Losartan can be decreased when combined with Floxuridine.
FluconazoleThe serum concentration of Losartan can be decreased when it is combined with Fluconazole.
FlucytosineThe metabolism of Losartan can be decreased when combined with Flucytosine.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Losartan.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Losartan.
FlunixinThe risk or severity of adverse effects can be increased when Losartan is combined with Flunixin.
FluorouracilThe metabolism of Losartan can be decreased when combined with Fluorouracil.
FluoxetineThe serum concentration of Losartan can be increased when it is combined with Fluoxetine.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Losartan.
FlupentixolThe serum concentration of Losartan can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Losartan can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Losartan can be increased when it is combined with Flurazepam.
FlurbiprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Flurbiprofen.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Losartan.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Losartan.
FluvoxamineThe metabolism of Losartan can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Losartan.
FosamprenavirThe metabolism of Losartan can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Losartan can be increased when it is combined with Fosaprepitant.
FosinoprilFosinopril may increase the hypotensive activities of Losartan.
FosphenytoinThe metabolism of Losartan can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypotensive activities of Losartan.
FurosemideThe risk or severity of adverse effects can be increased when Losartan is combined with Furosemide.
Fusidic AcidThe serum concentration of Losartan can be increased when it is combined with Fusidic Acid.
GavestinelThe metabolism of Gavestinel can be decreased when combined with Losartan.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Losartan.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Losartan.
GemfibrozilThe metabolism of Losartan can be decreased when combined with Gemfibrozil.
GenisteinThe serum concentration of Losartan can be increased when it is combined with Genistein.
GliclazideThe metabolism of Gliclazide can be decreased when combined with Losartan.
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Losartan.
GlipizideThe metabolism of Glipizide can be decreased when combined with Losartan.
GlyburideThe serum concentration of Losartan can be increased when it is combined with Glyburide.
GlyburideThe metabolism of Glyburide can be decreased when combined with Losartan.
GlycerolThe serum concentration of Losartan can be increased when it is combined with Glycerol.
GlyphosateThe metabolism of Losartan can be decreased when combined with Glyphosate.
Gramicidin DThe serum concentration of Losartan can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Losartan.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Losartan.
GriseofulvinThe metabolism of Losartan can be decreased when combined with Griseofulvin.
GuanabenzGuanabenz may increase the hypotensive activities of Losartan.
GuanadrelGuanadrel may increase the hypotensive activities of Losartan.
GuanethidineLosartan may increase the hypotensive activities of Guanethidine.
GuanfacineLosartan may increase the hypotensive activities of Guanfacine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Losartan.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Losartan.
HaloproginThe metabolism of Losartan can be decreased when combined with Haloprogin.
HalothaneThe metabolism of Halothane can be decreased when combined with Losartan.
HeparinHeparin may increase the hyperkalemic activities of Losartan.
HexamethoniumLosartan may increase the hypotensive activities of Hexamethonium.
HexetidineThe metabolism of Losartan can be decreased when combined with Hexetidine.
HexobarbitalHexobarbital may increase the hypotensive activities of Losartan.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Losartan.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Losartan.
HMPL-004The risk or severity of adverse effects can be increased when Losartan is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Losartan.
HydralazineLosartan may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideLosartan may increase the hypotensive activities of Hydrochlorothiazide.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Losartan.
HydroflumethiazideLosartan may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Losartan.
IbuprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Losartan is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Losartan is combined with Icatibant.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Losartan.
IdelalisibThe serum concentration of Losartan can be increased when it is combined with Idelalisib.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Losartan.
IloprostIloprost may increase the hypotensive activities of Losartan.
ImatinibThe metabolism of Losartan can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Losartan.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Losartan.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Losartan.
IndapamideLosartan may increase the hypotensive activities of Indapamide.
IndenololLosartan may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Losartan can be decreased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Losartan.
indisulamThe metabolism of indisulam can be decreased when combined with Losartan.
IndomethacinThe risk or severity of adverse effects can be increased when Losartan is combined with Indomethacin.
IndomethacinThe serum concentration of Losartan can be increased when it is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Indoprofen.
IndoraminLosartan may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Losartan.
IproniazidIproniazid may increase the hypotensive activities of Losartan.
IrbesartanLosartan may increase the hypotensive activities of Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Losartan.
IsavuconazoniumThe metabolism of Losartan can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Losartan.
IsoconazoleThe metabolism of Losartan can be decreased when combined with Isoconazole.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Losartan is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Losartan is combined with Isosorbide Mononitrate.
IsoxicamThe risk or severity of adverse effects can be increased when Losartan is combined with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Losartan is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Losartan.
ItraconazoleThe metabolism of Losartan can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Losartan can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Losartan.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Losartan.
KebuzoneThe risk or severity of adverse effects can be increased when Losartan is combined with Kebuzone.
KetamineThe serum concentration of Losartan can be increased when it is combined with Ketamine.
KetamineThe metabolism of Ketamine can be decreased when combined with Losartan.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Losartan.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Losartan.
KetoconazoleThe metabolism of Losartan can be decreased when combined with Ketoconazole.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Losartan.
KetoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Losartan is combined with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Losartan.
LacidipineLosartan may increase the hypotensive activities of Lacidipine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Losartan.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Losartan.
LansoprazoleThe serum concentration of Losartan can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Losartan can be increased when it is combined with Lapatinib.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Losartan.
LatanoprostLatanoprost may increase the hypotensive activities of Losartan.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Losartan.
LeflunomideThe risk or severity of adverse effects can be increased when Losartan is combined with Leflunomide.
LeflunomideThe metabolism of Losartan can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Losartan.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Losartan.
LercanidipineLercanidipine may increase the hypotensive activities of Losartan.
LesinuradThe metabolism of Lesinurad can be decreased when combined with Losartan.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Losartan.
LevobunololThe risk or severity of adverse effects can be increased when Losartan is combined with Levobunolol.
LevodopaLosartan may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Losartan.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Losartan.
LevothyroxineThe serum concentration of Losartan can be decreased when it is combined with Levothyroxine.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Losartan.
LidocaineThe serum concentration of Losartan can be increased when it is combined with Lidocaine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Losartan.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Losartan.
LiothyronineThe serum concentration of Losartan can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Losartan can be decreased when it is combined with Liotrix.
LisinoprilLosartan may increase the hypotensive activities of Lisinopril.
LithiumThe serum concentration of Lithium can be increased when it is combined with Losartan.
LofexidineLosartan may increase the hypotensive activities of Lofexidine.
LomitapideThe serum concentration of Losartan can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Losartan.
LopinavirThe serum concentration of Losartan can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Losartan can be increased when it is combined with Loratadine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Losartan.
LornoxicamThe risk or severity of adverse effects can be increased when Losartan is combined with Lornoxicam.
LovastatinThe metabolism of Losartan can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Loxoprofen.
LuliconazoleThe serum concentration of Losartan can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Losartan can be decreased when it is combined with Lumacaftor.
LumiracoxibThe risk or severity of adverse effects can be increased when Losartan is combined with Lumiracoxib.
MacitentanLosartan may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Losartan is combined with Magnesium salicylate.
ManidipineLosartan may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Losartan is combined with Mannitol.
MaprotilineThe serum concentration of Losartan can be increased when it is combined with Maprotiline.
MasoprocolThe risk or severity of adverse effects can be increased when Losartan is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Losartan.
MebendazoleThe serum concentration of Losartan can be increased when it is combined with Mebendazole.
MecamylamineMecamylamine may increase the hypotensive activities of Losartan.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Mefenamic acid.
MefloquineThe serum concentration of Losartan can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Losartan can be increased when it is combined with Megestrol acetate.
MelatoninThe metabolism of Melatonin can be decreased when combined with Losartan.
MeloxicamThe risk or severity of adverse effects can be increased when Losartan is combined with Meloxicam.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Losartan.
MeprobamateThe serum concentration of Losartan can be increased when it is combined with Meprobamate.
MesalazineThe risk or severity of adverse effects can be increased when Losartan is combined with Mesalazine.
MestranolThe metabolism of Mestranol can be decreased when combined with Losartan.
MetamizoleThe risk or severity of adverse effects can be increased when Losartan is combined with Metamizole.
MethadoneThe serum concentration of Losartan can be increased when it is combined with Methadone.
MethadoneThe metabolism of Methadone can be decreased when combined with Losartan.
MethazolamideThe risk or severity of adverse effects can be increased when Losartan is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Losartan.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Losartan.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Losartan.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Losartan.
MethyldopaLosartan may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Losartan.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Losartan.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Losartan.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Losartan.
MetipranololLosartan may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Losartan.
MetoprololMetoprolol may increase the hypotensive activities of Losartan.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Losartan.
MevastatinThe metabolism of Losartan can be decreased when combined with Mevastatin.
MibefradilLosartan may increase the hypotensive activities of Mibefradil.
MicafunginThe metabolism of Losartan can be decreased when combined with Micafungin.
MiconazoleThe metabolism of Losartan can be decreased when combined with Miconazole.
MidazolamThe serum concentration of Losartan can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Losartan.
MifepristoneThe metabolism of Losartan can be decreased when combined with Mifepristone.
MiltefosineThe metabolism of Losartan can be decreased when combined with Miltefosine.
MinaprineMinaprine may increase the hypotensive activities of Losartan.
MinoxidilMinoxidil may increase the hypotensive activities of Losartan.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Losartan.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Losartan.
MitomycinThe serum concentration of Losartan can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Losartan can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Losartan can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Losartan.
MoclobemideMoclobemide may increase the hypotensive activities of Losartan.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Losartan.
ModafinilThe serum concentration of Losartan can be decreased when it is combined with Modafinil.
MoexiprilLosartan may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Losartan.
MonensinThe metabolism of Losartan can be decreased when combined with Monensin.
MontelukastThe metabolism of Montelukast can be decreased when combined with Losartan.
MorphineThe serum concentration of Morphine can be increased when it is combined with Losartan.
MoxonidineLosartan may increase the hypotensive activities of Moxonidine.
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Losartan.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Losartan is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Mycophenolic acid.
MyxothiazolThe metabolism of Losartan can be decreased when combined with Myxothiazol.
NabumetoneThe risk or severity of adverse effects can be increased when Losartan is combined with Nabumetone.
NadololLosartan may increase the hypotensive activities of Nadolol.
NadroparinNadroparin may increase the hyperkalemic activities of Losartan.
NafcillinThe serum concentration of Losartan can be decreased when it is combined with Nafcillin.
NaftifineThe metabolism of Losartan can be decreased when combined with Naftifine.
NaftifineThe risk or severity of adverse effects can be increased when Losartan is combined with Naftifine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Losartan.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Losartan.
NaltrexoneThe serum concentration of Losartan can be increased when it is combined with Naltrexone.
NaproxenThe risk or severity of adverse effects can be increased when Losartan is combined with Naproxen.
NaringeninThe serum concentration of Losartan can be increased when it is combined with Naringenin.
NatamycinThe metabolism of Losartan can be decreased when combined with Natamycin.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Losartan.
NCX 4016The risk or severity of adverse effects can be increased when Losartan is combined with NCX 4016.
NebivololLosartan may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Losartan can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Losartan can be decreased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Losartan.
NeostigmineThe serum concentration of Losartan can be increased when it is combined with Neostigmine.
NepafenacThe risk or severity of adverse effects can be increased when Losartan is combined with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Losartan is combined with Nesiritide.
NetupitantThe serum concentration of Losartan can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Losartan.
NevirapineThe metabolism of Losartan can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Losartan.
NicardipineNicardipine may increase the hypotensive activities of Losartan.
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Losartan.
NicorandilNicorandil may increase the hypotensive activities of Losartan.
NicotineThe metabolism of Nicotine can be decreased when combined with Losartan.
NifedipineThe risk or severity of adverse effects can be increased when Losartan is combined with Nifedipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Losartan is combined with Niflumic Acid.
NiguldipineLosartan may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Losartan can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Losartan.
NilvadipineLosartan may increase the hypotensive activities of Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Losartan is combined with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Losartan.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Losartan.
NisoldipineNisoldipine may increase the hypotensive activities of Losartan.
NitrazepamThe serum concentration of Losartan can be increased when it is combined with Nitrazepam.
NitrendipineLosartan may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Losartan is combined with Nitroglycerin.
NitroprussideNitroprusside may increase the hypotensive activities of Losartan.
NitroxolineThe metabolism of Losartan can be decreased when combined with Nitroxoline.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Losartan.
NorethisteroneThe serum concentration of Losartan can be decreased when it is combined with Norethisterone.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Losartan.
NystatinThe metabolism of Losartan can be decreased when combined with Nystatin.
ObinutuzumabLosartan may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Losartan.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Losartan.
OlaparibThe metabolism of Losartan can be decreased when combined with Olaparib.
OlmesartanOlmesartan may increase the hypotensive activities of Losartan.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Losartan.
OlopatadineThe risk or severity of adverse effects can be increased when Losartan is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Losartan is combined with Olsalazine.
OmapatrilatLosartan may increase the hypotensive activities of Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Losartan.
OmeprazoleThe serum concentration of Losartan can be increased when it is combined with Omeprazole.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Losartan.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Losartan.
OrgoteinThe risk or severity of adverse effects can be increased when Losartan is combined with Orgotein.
OsimertinibThe serum concentration of Losartan can be increased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Losartan.
OxaprozinThe risk or severity of adverse effects can be increased when Losartan is combined with Oxaprozin.
OxiconazoleThe metabolism of Losartan can be decreased when combined with Oxiconazole.
OxprenololLosartan may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Oxyphenbutazone.
P-NitrophenolThe serum concentration of Losartan can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Losartan can be increased when it is combined with Paclitaxel.
pafuramidineThe metabolism of Losartan can be decreased when combined with pafuramidine.
PalbociclibThe serum concentration of Losartan can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Losartan can be increased when it is combined with Palmitic Acid.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Losartan.
PantoprazoleThe serum concentration of Losartan can be increased when it is combined with Pantoprazole.
PapaverineThe risk or severity of adverse effects can be increased when Losartan is combined with Papaverine.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Losartan.
ParecoxibThe risk or severity of adverse effects can be increased when Losartan is combined with Parecoxib.
PargylineLosartan may increase the hypotensive activities of Pargyline.
ParnaparinParnaparin may increase the hyperkalemic activities of Losartan.
ParoxetineThe serum concentration of Losartan can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Losartan.
PenbutololLosartan may increase the hypotensive activities of Penbutolol.
PentamidineThe metabolism of Losartan can be decreased when combined with Pentamidine.
PentobarbitalPentobarbital may increase the hypotensive activities of Losartan.
PentoliniumLosartan may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Losartan.
PerindoprilLosartan may increase the hypotensive activities of Perindopril.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Losartan.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Losartan.
PhenelzinePhenelzine may increase the hypotensive activities of Losartan.
PheniprazinePheniprazine may increase the hypotensive activities of Losartan.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Losartan.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Losartan.
PhenoxybenzamineLosartan may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Losartan.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Losartan.
PhentolamineLosartan may increase the hypotensive activities of Phentolamine.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Phenylbutazone.
PhenytoinThe metabolism of Losartan can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Losartan.
PimecrolimusThe risk or severity of adverse effects can be increased when Losartan is combined with Pimecrolimus.
PimozideThe serum concentration of Losartan can be increased when it is combined with Pimozide.
PinacidilLosartan may increase the hypotensive activities of Pinacidil.
PindololLosartan may increase the hypotensive activities of Pindolol.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Losartan.
PirfenidoneThe risk or severity of adverse effects can be increased when Losartan is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Losartan.
PiroxicamThe risk or severity of adverse effects can be increased when Losartan is combined with Piroxicam.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Losartan.
PivhydrazinePivhydrazine may increase the hypotensive activities of Losartan.
Platelet Activating FactorThe serum concentration of Losartan can be decreased when it is combined with Platelet Activating Factor.
PolythiazideLosartan may increase the hypotensive activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Losartan.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Losartan.
PosaconazoleThe metabolism of Losartan can be decreased when combined with Posaconazole.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Losartan.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Losartan.
PrazosinPrazosin may increase the hypotensive activities of Losartan.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Losartan.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Losartan.
PrimidonePrimidone may increase the hypotensive activities of Losartan.
ProbenecidThe serum concentration of Losartan can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Losartan can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Losartan.
ProguanilThe metabolism of Proguanil can be decreased when combined with Losartan.
PromazineThe metabolism of Promazine can be decreased when combined with Losartan.
PromethazineThe serum concentration of Losartan can be increased when it is combined with Promethazine.
PropacetamolThe risk or severity of adverse effects can be increased when Losartan is combined with Propacetamol.
PropafenoneThe serum concentration of Losartan can be increased when it is combined with Propafenone.
PropofolThe metabolism of Propofol can be decreased when combined with Losartan.
PropranololPropranolol may increase the hypotensive activities of Losartan.
ProtriptylineThe serum concentration of Losartan can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Losartan.
PTC299The risk or severity of adverse effects can be increased when Losartan is combined with PTC299.
PyrimethamineThe metabolism of Losartan can be decreased when combined with Pyrimethamine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Losartan.
QuercetinThe serum concentration of Losartan can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Losartan is combined with Quetiapine.
QuinacrineThe serum concentration of Losartan can be increased when it is combined with Quinacrine.
QuinaprilLosartan may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Losartan can be increased when it is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Losartan.
QuinineThe serum concentration of Quinine can be increased when it is combined with Losartan.
RabeprazoleThe metabolism of Losartan can be decreased when combined with Rabeprazole.
RadicicolThe metabolism of Losartan can be decreased when combined with Radicicol.
RamiprilRamipril may increase the hypotensive activities of Losartan.
RanitidineThe serum concentration of Losartan can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Losartan.
RasagilineRasagiline may increase the hypotensive activities of Losartan.
ReboxetineThe serum concentration of Losartan can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Losartan can be increased when it is combined with Regorafenib.
RemikirenRemikiren may increase the hypotensive activities of Losartan.
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Losartan.
RescinnamineLosartan may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Losartan.
ResveratrolThe risk or severity of adverse effects can be increased when Losartan is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Losartan.
RifabutinThe metabolism of Losartan can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Losartan can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Losartan.
RifapentineThe metabolism of Losartan can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Losartan.
RilpivirineThe serum concentration of Losartan can be increased when it is combined with Rilpivirine.
RiociguatLosartan may increase the hypotensive activities of Riociguat.
RisperidoneLosartan may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Losartan can be decreased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Losartan.
RituximabLosartan may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Losartan.
RofecoxibThe risk or severity of adverse effects can be increased when Losartan is combined with Rofecoxib.
RolapitantThe serum concentration of Losartan can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Losartan.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Losartan.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Losartan.
SafrazineSafrazine may increase the hypotensive activities of Losartan.
SalicylamideThe risk or severity of adverse effects can be increased when Losartan is combined with Salicylamide.
Salicylhydroxamic AcidThe metabolism of Losartan can be decreased when combined with Salicylhydroxamic Acid.
Salicylic acidThe metabolism of Losartan can be decreased when combined with Salicylic acid.
Salicylic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Losartan is combined with Salsalate.
SaprisartanLosartan may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Losartan can be decreased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Losartan.
ScopolamineThe serum concentration of Losartan can be increased when it is combined with Scopolamine.
SecobarbitalSecobarbital may increase the hypotensive activities of Losartan.
SelegilineSelegiline may increase the hypotensive activities of Losartan.
SelegilineThe metabolism of Selegiline can be decreased when combined with Losartan.
SelexipagLosartan may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Losartan is combined with Seratrodast.
SertaconazoleThe metabolism of Losartan can be decreased when combined with Sertaconazole.
SertralineThe serum concentration of Losartan can be increased when it is combined with Sertraline.
SertralineThe metabolism of Sertraline can be decreased when combined with Losartan.
SildenafilSildenafil may increase the antihypertensive activities of Losartan.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Losartan.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Losartan.
SiltuximabThe serum concentration of Losartan can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Losartan can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Losartan can be increased when it is combined with Simvastatin.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Losartan.
SinefunginThe metabolism of Losartan can be decreased when combined with Sinefungin.
SirolimusThe metabolism of Losartan can be decreased when combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Losartan.
SitaxentanLosartan may increase the hypotensive activities of Sitaxentan.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Losartan.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Losartan.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Losartan.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Losartan.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Losartan.
SpiraprilLosartan may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Losartan.
SRT501The risk or severity of adverse effects can be increased when Losartan is combined with SRT501.
St. John's WortThe serum concentration of Losartan can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Losartan can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Losartan can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Losartan can be decreased when it is combined with Streptozocin.
SulconazoleThe metabolism of Losartan can be decreased when combined with Sulconazole.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Losartan.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Losartan.
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Losartan.
SulfasalazineThe risk or severity of adverse effects can be increased when Losartan is combined with Sulfasalazine.
SulfinpyrazoneThe serum concentration of Losartan can be increased when it is combined with Sulfinpyrazone.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Losartan.
SulfisoxazoleThe metabolism of Losartan can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Losartan is combined with Sulindac.
SumatriptanThe serum concentration of Losartan can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Losartan can be increased when it is combined with Sunitinib.
SuprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Suprofen.
TacrineThe serum concentration of Losartan can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Losartan can be decreased when it is combined with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Losartan.
TadalafilTadalafil may increase the antihypertensive activities of Losartan.
TamoxifenThe serum concentration of Losartan can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Losartan.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Losartan.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Losartan.
TavaboroleThe metabolism of Losartan can be decreased when combined with Tavaborole.
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Losartan.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Losartan.
TelaprevirThe metabolism of Losartan can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Losartan.
TelithromycinThe metabolism of Losartan can be decreased when combined with Telithromycin.
TelmisartanLosartan may increase the hypotensive activities of Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Losartan.
TemocaprilLosartan may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Losartan.
TenoxicamThe risk or severity of adverse effects can be increased when Losartan is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Losartan is combined with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Losartan is combined with Terazosin.
TerbinafineThe metabolism of Losartan can be decreased when combined with Terbinafine.
TerconazoleThe metabolism of Losartan can be decreased when combined with Terconazole.
TerfenadineThe serum concentration of Losartan can be increased when it is combined with Terfenadine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Losartan.
TeriflunomideThe risk or severity of adverse effects can be increased when Losartan is combined with Teriflunomide.
TeriflunomideThe metabolism of Losartan can be decreased when combined with Teriflunomide.
TerlipressinLosartan may increase the hypotensive activities of Terlipressin.
TesmilifeneThe serum concentration of Losartan can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Losartan can be increased when it is combined with Testosterone.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Losartan.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Losartan.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Losartan.
ThiamylalThiamylal may increase the hypotensive activities of Losartan.
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Losartan.
ThiopentalThiopental may increase the hypotensive activities of Losartan.
ThymolThe metabolism of Losartan can be decreased when combined with Thymol.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Tiaprofenic acid.
TiboloneLosartan may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Losartan.
TiclopidineThe metabolism of Losartan can be decreased when combined with Ticlopidine.
TicrynafenLosartan may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Losartan.
TinzaparinTinzaparin may increase the hyperkalemic activities of Losartan.
TioconazoleThe metabolism of Losartan can be decreased when combined with Tioconazole.
TizanidineThe risk or severity of adverse effects can be increased when Losartan is combined with Tizanidine.
TocilizumabThe serum concentration of Losartan can be decreased when it is combined with Tocilizumab.
TolazolineLosartan may increase the hypotensive activities of Tolazoline.
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Losartan.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Losartan is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Losartan is combined with Tolmetin.
TolnaftateThe metabolism of Losartan can be decreased when combined with Tolnaftate.
ToloxatoneToloxatone may increase the hypotensive activities of Losartan.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Losartan.
TolvaptanTolvaptan may increase the hyperkalemic activities of Losartan.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Losartan.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Losartan.
TorasemideTorasemide may increase the hypotensive activities of Losartan.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Losartan.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Losartan.
TrandolaprilTrandolapril may increase the hypotensive activities of Losartan.
TranilastThe risk or severity of adverse effects can be increased when Losartan is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Losartan.
TranylcypromineTranylcypromine may increase the hypotensive activities of Losartan.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Losartan.
TravoprostTravoprost may increase the hypotensive activities of Losartan.
TrazodoneThe serum concentration of Losartan can be decreased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the hypotensive activities of Losartan.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Losartan.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Losartan.
TrichlormethiazideLosartan may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineThe serum concentration of Losartan can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Losartan can be increased when it is combined with Triflupromazine.
TrimazosinLosartan may increase the hypotensive activities of Trimazosin.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Losartan.
TrimethaphanLosartan may increase the hypotensive activities of Trimethaphan.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Losartan.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Losartan.
TrimetrexateThe metabolism of Losartan can be decreased when combined with Trimetrexate.
TrimipramineThe serum concentration of Losartan can be increased when it is combined with Trimipramine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Losartan.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Losartan is combined with Trisalicylate-choline.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Losartan.
TroleandomycinThe serum concentration of Losartan can be increased when it is combined with Troleandomycin.
UdenafilUdenafil may increase the antihypertensive activities of Losartan.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Losartan.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Losartan.
UnoprostoneLosartan may increase the hypotensive activities of Unoprostone.
ValdecoxibThe risk or severity of adverse effects can be increased when Losartan is combined with Valdecoxib.
Valproic AcidThe metabolism of Losartan can be decreased when combined with Valproic Acid.
ValsartanValsartan may increase the hypotensive activities of Losartan.
VardenafilVardenafil may increase the antihypertensive activities of Losartan.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Losartan.
VenlafaxineThe metabolism of Losartan can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Losartan.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Losartan.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Losartan.
VinblastineThe serum concentration of Losartan can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Losartan.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Losartan.
VincristineThe serum concentration of Losartan can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Losartan can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Losartan.
VoriconazoleThe metabolism of Losartan can be decreased when combined with Voriconazole.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Losartan.
WarfarinThe metabolism of Warfarin can be decreased when combined with Losartan.
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Losartan.
XylometazolineLosartan may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Losartan.
ZafirlukastThe metabolism of Losartan can be decreased when combined with Zafirlukast.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Losartan.
ZaltoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Zaltoprofen.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Losartan.
ZileutonThe risk or severity of adverse effects can be increased when Losartan is combined with Zileuton.
ZimelidineThe serum concentration of Losartan can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Losartan can be decreased when combined with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Losartan.
ZomepiracThe risk or severity of adverse effects can be increased when Losartan is combined with Zomepirac.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Losartan.
Food Interactions
  • Take without regard to meals. Take at same time each day. Food delays absorption, but does not affect the extent of absorption.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Sardo MA, Castaldo M, Cinquegrani M, Bonaiuto M, Fontana L, Campo S, Campo GM, Altavilla D, Saitta A: Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive patients. Angiology. 2004 Mar-Apr;55(2):195-203. [PubMed:15026875 ]
  3. Dickstein K, Timmermans P, Segal R: Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure. Expert Opin Investig Drugs. 1998 Nov;7(11):1897-914. [PubMed:15991937 ]
  4. Anand-Srivastava MB, Palaparti A: Angiotensin-II-induced enhanced expression of Gi proteins is attenuated by losartan in A10 vascular smooth muscle cells: role of AT1 receptors. Can J Physiol Pharmacol. 2003 Feb;81(2):150-8. [PubMed:12710529 ]
  5. Rocha I, Bras-Rosario L, Amparo-Barros M, Silva-Carvalho L: Angiotensin AT1 receptor antagonist losartan and the defence reaction in the anaesthetised rat. Effect on the carotid chemoreflex. Exp Physiol. 2003 May;88(3):309-14. [PubMed:12719755 ]
  6. Guan J, Cheng DY, Chen XJ, Zhang Y, Wang H, Su QL: [The effects of losartan on pulmonary arterial collagen and AT1 in chronic hypoxic rats]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2004 Nov;35(6):774-7. [PubMed:15573751 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Song JC, White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy. 2000 Feb;20(2):130-9. [PubMed:10678291 ]
  2. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F, Eliasson E, Dahl ML: Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther. 2002 Jan;71(1):89-98. [PubMed:11823761 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Song JC, White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy. 2000 Feb;20(2):130-9. [PubMed:10678291 ]
  2. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A3
Uniprot ID:
P35503
Molecular Weight:
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein kinase c binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A10
Uniprot ID:
Q9HAW8
Molecular Weight:
59809.075 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. The major substrates of this isozyme are eugenol > 4-methylumbelliferone > dihydrotestosterone (DHT) > androstane-3-alpha,17-beta-diol (3-alpha-diol) > testosterone > androsterone (ADT).
Gene Name:
UGT2B17
Uniprot ID:
O75795
Molecular Weight:
61094.915 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
  2. Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71. [PubMed:8621716 ]
  3. Soldner A, Benet LZ, Mutschler E, Christians U: Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 2000 Mar;129(6):1235-43. [PubMed:10725273 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [PubMed:10049739 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Urate transmembrane transporter activity
Specific Function:
Required for efficient urate re-absorption in the kidney. Regulates blood urate levels. Mediates saturable urate uptake by facilitating the exchange of urate against organic anions.
Gene Name:
SLC22A12
Uniprot ID:
Q96S37
Molecular Weight:
59629.57 Da
References
  1. Lipkowitz MS: Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 2012 Apr;14(2):179-88. doi: 10.1007/s11926-012-0240-z. [PubMed:22359229 ]
  2. Burnier M, Roch-Ramel F, Brunner HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996 Jun;49(6):1787-90. [PubMed:8743498 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sugar:proton symporter activity
Specific Function:
Transport urate and fructose. May have a role in the urate reabsorption by proximal tubules. Also transports glucose at low rate.
Gene Name:
SLC2A9
Uniprot ID:
Q9NRM0
Molecular Weight:
58701.205 Da
References
  1. Lipkowitz MS: Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 2012 Apr;14(2):179-88. doi: 10.1007/s11926-012-0240-z. [PubMed:22359229 ]
  2. Burnier M, Roch-Ramel F, Brunner HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996 Jun;49(6):1787-90. [PubMed:8743498 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23